Chardan Capital Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
Chardan Capital analyst Keay Nakae has reiterated a 'Buy' rating on Arbutus Biopharma (NASDAQ:ABUS) and maintained a price target of $6.
August 04, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arbutus Biopharma's stock may see positive movement as Chardan Capital maintains a 'Buy' rating and a price target of $6.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target of $6 by Chardan Capital indicates a positive outlook for Arbutus Biopharma, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100